Recent news highlights that the Factor XI inhibitor space is emerging as the next significant advancement in cardiovascular care, and at Ribo, we are proud to be at the forefront of this development.
FXI inhibition has the potential to address a substantial unmet need and to represent a breakthrough in anti-coagulation therapy for millions of patients who are currently not receiving adequate treatment. Our siRNA approach for FXI inhibition offers a long duration of action compared to other modalities, such as antibodies, and allows for rapid reversibility if needed.
Our Phase 2 program is progressing well and according to plan. Ribo’s siRNA asset, RBD4059, is poised to offer a truly differentiated therapy in this space.
Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
BEIJING, China & GOTHENBURG, Sweden — 2025-10-24 — Suzhou Ribo
